APA (7th ed.) Citation

Schadendorf, D., Robert, C., Dummer, R., Cruz-Merino, L. d. l., Ascierto, P. A., Kirkwood, J. M., . . . Krepler, C. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Schadendorf, Dirk, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Outcomes in Histopathologic Subgroups from the Randomized, Double-blind, Phase 3 KEYNOTE-716 Trial. BMJ Publishing Group.

MLA (9th ed.) Citation

Schadendorf, Dirk, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Outcomes in Histopathologic Subgroups from the Randomized, Double-blind, Phase 3 KEYNOTE-716 Trial. BMJ Publishing Group.